Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction

• DOI: 10.1016/j.redox.2024.103129
• Publication Date: 2024-03-19T17:42:43Z
• Authors: Xiaoping Li; Wenbin Luo; Yang Tang; Jiangjiao Wu; Junkai Zhang; Shengnan Chen; Lu Zhou; Yu Tao; Yuanjuan Tang; Fengxian Wang; Yu Huang; Pedro A. Jose; Li Guo; Chunyu Zeng
• Keywords: Cardiotoxicity; Semaglutide; Cardiac Fibrosis

Doxorubicin is a powerful chemotherapeutic agent for cancer, whose use limited due to its potential cardiotoxicity. Semaglutide (SEMA), novel analog of glucagon-like peptide-1 (GLP-1), has received widespread attention the treatment diabetes. However, increasing evidence highlighted therapeutic benefits on cardiac function. Therefore, objective this study was examine efficacy semaglutide in ameliorating doxorubicin-induced